In patients requiring daily oral glucocorticoid therapy to maintain asthma control, mepolizumab had a significant glucocorticoid-sparing effect, reduced exacerbations, and improved control of asthma symptoms. (Funded by GlaxoSmithKline; SIRIUS ClinicalTrials.gov number, NCT01691508.).
No takes yet. Share an insight, caveat, or question.
Bel et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: